Scarica l'app Stockscreener
69.23
2.73%
1.84
Dopo l'orario di chiusura:
68.68
-0.55
-0.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$67.39
Aprire:
$67.4
Volume 24 ore:
4.61M
Relative Volume:
1.13
Capitalizzazione di mercato:
$27.74B
Reddito:
$4.03B
Utile/perdita netta:
$576.20M
Rapporto P/E:
48.41
EPS:
1.43
Flusso di cassa netto:
$630.70M
1 W Prestazione:
+14.07%
1M Prestazione:
-2.07%
6M Prestazione:
+3.17%
1 anno Prestazione:
-48.55%
Intervallo 1D:
$66.98
$69.32
Intervallo di 1 settimana:
$59.62
$73.50
Portata 52W:
$57.52
$139.24
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
69.23 | 27.74B | 4.03B | 576.20M | 630.70M | 1.43 |
|
ABT
Abbott Laboratories
|
126.22 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
94.23 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.80 | 132.37B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.37 | 105.64B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.76 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
RBC Cuts Price Target on DexCom to $100 From $115, Keeps Outperform Rating - MarketScreener
BTIG Adjusts DexCom (DXCM) Price Target Ahead of MedTech Q1 Resu - GuruFocus
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance - MSN
FDA clears Dexcom G7 15 Day - BioWorld MedTech
What Does the Market Think About DexCom? - Benzinga
What to Expect From DexCom's Next Quarterly Earnings Report - TradingView
What To Expect From DexCom's Next Quarterly Earnings Report - Barchart.com
DexCom (DXCM) Anticipates Growth Driven by Strategic Initiatives - GuruFocus
FDA clears Dexcom G7 15-Day continuous glucose monitor - TechTarget
Mizuho Initiates Coverage of DexCom (XTRA:DC4) with Outperform Recommendation - Nasdaq
Dexcom G7 15 Day CGM system cleared by FDA for adults - Investing.com South Africa
Dexcom G7 15 Day CGM System Cleared by FDA - Patient Care Online
DexCom (DXCM) Faces Investor Backlash After Disappointing Earnings ReportHagens Berman - ACCESS Newswire
Dexcom nets FDA clearance for 15-day CGM - MedTech Dive
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomPanhandle - Panhandle - News Channel
FDA Approves New DexCom Diabetes Device - Yahoo Finance
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch - Benzinga
Stifel maintains DexCom stock Buy rating, $100 target post FDA nod - Investing.com Australia
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance - Barron's
Dexcom wins FDA nod for 15-day CGM - MassDevice
DexCom (DXCM) Faces Market Challenges Amid Strategic Changes - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. LawsuitDXCM - ACCESS Newswire
DexCom (DXCM) Gains on FDA Approval for G7 15 Day Monitoring Sys - GuruFocus
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction - The Motley Fool
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday - Benzinga
DexCom (DXCM) Receives FDA Clearance for Enhanced Glucose Monito - GuruFocus
DexCom Says G7 15 Day Continuous Glucose Monitoring System Gets US FDA Clearance - MarketScreener
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wea - GuruFocus
Dexcom stock rises on FDA nod for new CGM (DXCM:NASDAQ) - Seeking Alpha
FDA OKs Dexcom G7 15-Day Continuous Glucose Monitor - Medical Product Outsourcing
DexCom shares rise on FDA clearance for new CGM system - Investing.com Australia
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System - Dexcom
Mizuho Initiates Coverage of DexCom (DXCM) with Outperform Recommendation - Nasdaq
What 6 Analyst Ratings Have To Say About DexCom - Benzinga
Mizuho Initiates DexCom at Outperform With $85 Price Target - MarketScreener
FDA Clears Dexcom G7 15 Day for Continuous Glucose Monitoring - Medical Professionals Reference
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM STOCK ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
PODD Stock Benefits From the Launch of Omnipod 5 in Canada - Yahoo Finance
DexCom, Inc. Class Action: Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024DXCM - ACCESS Newswire
DexCom (NasdaqGS:DXCM) Down 12% As Jon Coleman Becomes Chief Commercial Officer - Yahoo Finance
Citigroup Adjusts DexCom Price Target to $80 From $104, Maintains Buy Rating - MarketScreener
DXCM INVESTIGATION UPDATE: DexCom, Inc. Investors with Losses on their Investment are Notified of Securities Fraud Investigation; Contact BFA Law for Details (Nasdaq:DXCM) - ACCESS Newswire
DXCM INVESTOR UPDATE: Suffer Losses on Your DexCom, Inc. Investment? Contact BFA Law by October 21 about Pending Class Action Lawsuit (Nasdaq:DXCM) - FinTech Futures
ATTENTION DexCom, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
DexCom, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
DXCM INVESTOR ALERT: DexCom, Inc. Investors are Notified to Contact BFA Law before October 21 Deadline in Class Action Lawsuit - ACCESS Newswire
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - MSN
Why We're Not Concerned Yet About DexCom, Inc.'s (NASDAQ:DXCM) 25% Share Price Plunge - simplywall.st
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. Lawsuit – DXCM - ACCESS Newswire
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):